JP2002517467A - 自閉症ならびに他の神経学的、行動学的、および免疫学的障害の治療に対するセクレチンの使用 - Google Patents

自閉症ならびに他の神経学的、行動学的、および免疫学的障害の治療に対するセクレチンの使用

Info

Publication number
JP2002517467A
JP2002517467A JP2000553127A JP2000553127A JP2002517467A JP 2002517467 A JP2002517467 A JP 2002517467A JP 2000553127 A JP2000553127 A JP 2000553127A JP 2000553127 A JP2000553127 A JP 2000553127A JP 2002517467 A JP2002517467 A JP 2002517467A
Authority
JP
Japan
Prior art keywords
secretin
effective amount
individual
disorder
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000553127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002517467A5 (cg-RX-API-DMAC7.html
Inventor
ヴィクトリア ベック
ベルナルド ライムランド
Original Assignee
リプリジェン コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リプリジェン コーポレーション filed Critical リプリジェン コーポレーション
Publication of JP2002517467A publication Critical patent/JP2002517467A/ja
Publication of JP2002517467A5 publication Critical patent/JP2002517467A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2235—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000553127A 1998-06-09 1999-06-09 自閉症ならびに他の神経学的、行動学的、および免疫学的障害の治療に対するセクレチンの使用 Withdrawn JP2002517467A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8857598P 1998-06-09 1998-06-09
US60/088,575 1998-06-09
US09/229,208 US6197746B1 (en) 1998-05-19 1999-01-13 Method of using secretin for treating autism
US09/229,208 1999-01-13
PCT/US1999/013061 WO1999064059A2 (en) 1998-06-09 1999-06-09 Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders

Publications (2)

Publication Number Publication Date
JP2002517467A true JP2002517467A (ja) 2002-06-18
JP2002517467A5 JP2002517467A5 (cg-RX-API-DMAC7.html) 2007-04-05

Family

ID=26778819

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000553127A Withdrawn JP2002517467A (ja) 1998-06-09 1999-06-09 自閉症ならびに他の神経学的、行動学的、および免疫学的障害の治療に対するセクレチンの使用

Country Status (8)

Country Link
US (3) US6197746B1 (cg-RX-API-DMAC7.html)
EP (1) EP1085901B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002517467A (cg-RX-API-DMAC7.html)
AT (1) ATE322283T1 (cg-RX-API-DMAC7.html)
AU (1) AU772911B2 (cg-RX-API-DMAC7.html)
CA (1) CA2333657A1 (cg-RX-API-DMAC7.html)
DE (1) DE69930739D1 (cg-RX-API-DMAC7.html)
WO (1) WO1999064059A2 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008532033A (ja) * 2005-02-28 2008-08-14 タイポジェン エイエス 自閉症や脳性麻痺などの精神疾患の予後判定方法
JP2013523769A (ja) * 2010-03-31 2013-06-17 アベラ ファーマスーティカルズ インコーポレイテッド 自閉症治療用ジメチルスルホキシド(dmso)製剤

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197746B1 (en) * 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
US6020310A (en) * 1997-05-19 2000-02-01 Repligen Corporation Method for assisting in differential diagnosis and treatment of autistic syndromes
US6020314A (en) * 1998-08-11 2000-02-01 Milkhaus Laboratory, Inc. Methods for treatment of neurological disorders
WO2001037801A1 (en) * 1999-11-22 2001-05-31 Rogoff Joseph A Secretin and secretin pharmaceuticals for treating attention deficit disorder
US6632429B1 (en) * 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US6534063B1 (en) 1999-12-17 2003-03-18 Joan M. Fallon Methods for treating pervasive development disorders
GB0008326D0 (en) * 2000-04-06 2000-05-24 Shs International Ltd Diagnosis and treatment of autism and related disorders
GB0016441D0 (en) 2000-07-04 2000-08-23 Pharmagene Lab Limited Therapeutic method
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US6660831B2 (en) * 2000-08-14 2003-12-09 Joan M. Fallon Method for diagnosing and treating dysautonomia and other dysautonomic conditions
CA2419285C (en) * 2000-08-25 2011-08-02 Research Corporation Technologies, Inc. New uses for amino acid anticonvulsants
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
GB0118383D0 (en) * 2001-07-27 2001-09-19 Pharmagene Lab Ltd Therapeutic methods
US6585996B1 (en) 2002-03-13 2003-07-01 Westlake Laboratories, Inc. Lipid-soluble thiamine derivatives in the treatment of autism
US8100844B2 (en) * 2002-04-25 2012-01-24 Ultraflex Systems, Inc. Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint
US20070154534A1 (en) * 2003-03-12 2007-07-05 Sheitman Brian B Use of secretin in the treatment of schizophrenia
EP1605960A2 (en) * 2003-03-12 2005-12-21 Repligen Corporation Use of secretin and secretin analogs to treat affective disorders
US8524665B2 (en) * 2003-05-13 2013-09-03 The Mclean Hospital Corporation Use of secretin in treatments of disorders associated with the amygdala
US7947285B2 (en) * 2003-12-12 2011-05-24 Fein Seymour H Methods for preventing post endoscopic retrograde cholangiopancreatography pancreatitis
US7381698B2 (en) * 2003-12-12 2008-06-03 Chirhoclin, Inc. Methods for treatment of acute pancreatitis
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
US20070034214A1 (en) * 2005-08-12 2007-02-15 Dochniak Michael J Method to affect the development of autism spectrum disorders
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
US9320780B2 (en) * 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
PL2318035T3 (pl) * 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
JP5684725B2 (ja) 2009-01-06 2015-03-18 キュレロン リミテッド ライアビリティ カンパニー 黄色ブドウ球菌感染の治療または予防のための組成物および方法ならびに表面上にいる黄色ブドウ球菌の根絶または低減のための組成物および方法
CA2747703C (en) 2009-01-06 2021-06-15 Curemark Llc Compositions and methods for the treatment or the prevention of infections by e. coli
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
EP2485744A4 (en) * 2009-10-09 2014-01-22 Prothera Inc COMPOSITIONS AND METHODS COMPRISING THE PEDIOCOCCUS TO REDUCE AT LEAST ONE SYMPTOM ASSOCIATED WITH DEVELOPMENT-INVASIVE DISORDER IN A PERSON IN WHICH A DEVELOPMENT-INVASIVE DISORDER HAS BEEN DIAGNOSED
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
US9931365B2 (en) 2010-09-28 2018-04-03 Lisa Geng Methods for treating neurological disorders using nutrient compositions
US8962042B2 (en) 2010-09-28 2015-02-24 Lisa Geng Methods for treating neurological disorders using nutrient compositions
DK2701733T3 (da) 2011-04-21 2019-05-27 Curemark Llc Forbindelser til behandling af neuropsykiatriske forstyrrelser
US9442092B2 (en) 2011-06-20 2016-09-13 Kerry Lane Methods for treatment of autism
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
WO2018191233A1 (en) 2017-04-10 2018-10-18 Curemark, Llc Compositions for treating addiction
US11318190B2 (en) 2017-05-05 2022-05-03 United States Government As Represented By The Department Of Veterans Affairs Methods and compositions for treating liver disease
CN109908120B (zh) * 2019-04-22 2022-04-19 井冈山大学 一种狭顶鳞毛蕨有效成分、提取方法及其应用
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833722A (en) 1971-03-16 1974-09-03 D Graybill Method for controlling allergies
JPS5029005B2 (cg-RX-API-DMAC7.html) * 1972-05-08 1975-09-19
US3987014A (en) 1974-01-10 1976-10-19 Becton, Dickinson And Company Secretin intermediates and derivatives
DE2615229C2 (de) 1976-04-08 1984-05-24 Hoechst Ag, 6230 Frankfurt Verfahren zur Herstellung und Reinigung von Sekretin
US4086220A (en) 1976-08-09 1978-04-25 G. D. Searle & Co. Fragments of secretin
EP0021184B1 (de) 1979-06-13 1984-02-08 Hoechst Aktiengesellschaft Sekretinpräparate mit verstärkter und protrahierter Wirkung, Verfahren zu ihrer Herstellung sowie Dihydroxybenzoyl-L-tyrosin
NZ196349A (en) 1980-03-07 1984-08-24 Interx Research Corp Enhancement of absorption rate of orally administered polar bioactive agents
JPS58140024A (ja) 1982-02-15 1983-08-19 Eisai Co Ltd セクレチンの精製方法
DE3328793A1 (de) 1983-08-10 1985-02-28 Hoechst Ag, 6230 Frankfurt Herstellung von sekretin
SE454513B (sv) 1985-03-11 1988-05-09 Kabigen Ab Humant sekretin samt kompositioner innehallande detta
JPS61277618A (ja) 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
US5008251A (en) 1986-03-27 1991-04-16 The Regents Of The University Of California Method of treating autism
US4994467A (en) 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
US5094837A (en) 1990-01-22 1992-03-10 Wayne State University Method for use of magnetic resonance imaging to image pancreas using secretin
US5225407A (en) 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
US5380872A (en) * 1992-07-14 1995-01-10 Glaxo Inc. Modulators of cholecystokinin
ES2154673T3 (es) 1993-01-29 2001-04-16 Aradigm Corp Suministro intrapulmonar de hormonas.
US5527825A (en) 1994-04-06 1996-06-18 University Of Arkansas Method of treating schizophrenia, tourette's syndrome, mania, autism, and obsessive compulsive disorder with inhibitors of brain nitric oxide synthase
US5560910A (en) * 1994-08-26 1996-10-01 Crandall; Wilson T. Topical anti-inflammatory composition and method
GB9417524D0 (en) 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
US5686311A (en) 1995-06-23 1997-11-11 The Children's Mercy Hospital Diagnosis of autism and treatment therefor
US6197746B1 (en) * 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
US6020310A (en) * 1997-05-19 2000-02-01 Repligen Corporation Method for assisting in differential diagnosis and treatment of autistic syndromes
CA2303484A1 (en) 1997-09-11 1999-03-18 The Regents Of The University Of California Plus end-directed microtubule motor required for chromosome congression

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008532033A (ja) * 2005-02-28 2008-08-14 タイポジェン エイエス 自閉症や脳性麻痺などの精神疾患の予後判定方法
JP2013523769A (ja) * 2010-03-31 2013-06-17 アベラ ファーマスーティカルズ インコーポレイテッド 自閉症治療用ジメチルスルホキシド(dmso)製剤

Also Published As

Publication number Publication date
EP1085901B1 (en) 2006-04-05
US6790825B2 (en) 2004-09-14
US20050249714A1 (en) 2005-11-10
US6197746B1 (en) 2001-03-06
DE69930739D1 (de) 2006-05-18
WO1999064059A3 (en) 2000-03-02
US20010049353A1 (en) 2001-12-06
ATE322283T1 (de) 2006-04-15
AU772911B2 (en) 2004-05-13
EP1085901A2 (en) 2001-03-28
AU4432299A (en) 1999-12-30
CA2333657A1 (en) 1999-12-16
WO1999064059A2 (en) 1999-12-16

Similar Documents

Publication Publication Date Title
US6790825B2 (en) Method of using secretin and compositions made therefrom for the treatment of autism and other neurological, behavioral and immunological disorders
RU2546520C2 (ru) Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
JP2002501616A (ja) 自閉的症候群を鑑別診断および治療する際の助けとするための方法
TW201119645A (en) Low frequency glatiramer acetate therapy
EP3817766A2 (en) Combination therapy with cgrp antagonists and clostridial derivatives
CN1711101A (zh) 孤独症及相似障碍的治疗
CN1249690A (zh) 通过共聚物-1的摄入或吸入治疗多发性硬化症
Glaser et al. Limbic encephalitis
JP2003521462A (ja) 男性における器質性勃起機能不全治療のための医薬品製造におけるアポモルヒネの使用
EA013591B1 (ru) Применение пептидных соединений для профилактики, облегчения и лечения головной боли и болезненных состояний, связанных с или вызванных распространяющейся кортикальной депрессией (csd)
BR112019017724A2 (pt) Sistemas depot de glatiramer para tratar formas progressivas de esclerose múltipla
RU2322985C2 (ru) Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости
EP4285898A1 (en) Pathway modulator, pharmaceutical composition having same, use thereof, and therapeutic method using same
CN114306207A (zh) 一种以棒棒糖为载体的口腔给药方法
RU2192817C2 (ru) Способ лечения частичной атрофии зрительного нерва
CN1175828C (zh) 一种抗房劳、抗衰老的药物组合物及其制备方法
RU2655763C2 (ru) Фармацевтическая композиция и способ лечения женских сексуальных дисфункций
CH649710A5 (de) Psychotropes arzneimittel.
US20190307851A1 (en) Prophylactic and therapeutic agent for rett syndrome (rtt) comprising ghrelin as active ingredient
WO2001037801A1 (en) Secretin and secretin pharmaceuticals for treating attention deficit disorder
SU1205915A1 (ru) Способ лечени аллергических заболеваний
IL311532A (en) Sublingual epinephrine formulations and methods of use
RU2411036C2 (ru) Способ терапии расстройств эрекции у мужчин
Babayan et al. Neuroleptics and antipsychotic drugs
SU1438797A1 (ru) Способ лечени вазомоторного ринита

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070206

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20070627

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070627